GYRE Gyre Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why GYRE matters now
Gyre Therapeutics, Inc. (GYRE) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.52 with -4.96% on the session and $595.9M in market capitalization; recent performance reads 1-month -0.16% and YTD -11.47%.
The latest financial table shown here is Q1 2026, with revenue of $22.5M, net income of $-8.6M, and EPS of $-0.10. Investors can compare that operating picture with valuation signals such as P/E 134.24 and FCF yield 0.5%.
The latest indexable market news headline is "Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm" from Newsfile Corp.
Additional event context on this page matters because analyst consensus is Buy with a median target of $17.00; recent insider activity includes Ye Weiguo filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
134.24
PEG
—
P/B
5.63
P/S
5.18
EV/EBITDA
180.59
DCF Value
$-0.61
FCF Yield
0.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
95.1%
Operating Margin
-0.1%
Net Margin
-5.4%
ROE
-6.3%
ROA
-3.9%
ROIC
0.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $22.5M | $-8.6M | $-0.10 |
| Q4 2025 | $37.2M | $-1.7M | $-0.02 |
| FY 2025 | $116.6M | $5.0M | $0.02 |
| Q3 2025 | $30.6M | $3.6M | $0.03 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$17.00
Target (Median)
$17.00
Target Range
$16.00 - $18.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
4.92
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.